Travecta Therapeutics develops a portfolio of product candidates engineered to cross the blood–brain barrier using its proprietary mVECTA platform. Its lead program is TVT-004, a non-opioid candidate targeting pain. The company plans to use the financing to advance TVT-004 into clinical trials in 2021. Travecta also intends to progress earlier-stage research programs in neuro-oncology and neuro-inflammation. The company is led by CEO Dr. Michael Shleifer and was founded by Dr. David Silver and Dr. Mahmood Ahmed together with the SPRIM Ventures team. Travecta is based in New York City and Singapore.

Total raised

$15M

Funding rounds

1

Latest round

Series A

Latest activity

May 2020